KN3601

KN3601 is an investigational dual-targeting chimeric antigen receptor (CAR) T-cell therapy designed to target both **CD19** and **B-cell maturation antigen (BCMA)**. Developed for the treatment of autoimmune disorders, specifically relapsed or refractory immune-mediated kidney diseases (such as lupus nephritis), KN3601 utilizes a dual-targeting approach to achieve more comprehensive depletion of pathogenic B cells and plasma cells. By targeting CD19 (expressed on B cells) and BCMA (expressed on long-lived plasma cells), the therapy aims to reset the immune system more effectively than single-target agents. The "U" designation typically suggests a universal or allogeneic platform, or a specific proprietary manufacturing process intended to enhance the accessibility and scalability of the treatment.

Other names

Anti-CD19/BCMA U CAR-T CellsCD19/BCMA Dual-Targeting CAR-T